CTTN: A Protein with Potential Drug Targets and Biomarkers for Diseases

Target Name: CTTN

NCBI ID: G2017

CTTN

CTTN: A Protein with Potential Drug Targets and Biomarkers for Diseases

CTTN, or Compound Transformative Target Network, is a protein that is expressed in various tissues throughout the body and plays a crucial role in the development and progression of many diseases. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The protein encoded by the CTTN gene is a transmembrane protein that contains four extracellular domains, a cytoplasmic tail, and a N-terminus that is involved in protein-protein interactions. It is characterized by a variety of unique features that make it an attractive target for drug development, including its ability to interact with a wide range of proteins, its stability and solubility, and its unique expression patterns across different tissues and organisms.

One of the key functions of CTTN is its role in cell signaling. It is involved in the regulation of cell adhesion, migration, and survival, and has been implicated in the development and progression of many diseases. For example, studies have shown that CTTN is involved in the development of cancer, and that its expression is associated with poor prognosis in patients with breast cancer.

In addition to its role in cell signaling, CTTN is also involved in the regulation of inflammation. It has been shown to play a key role in the regulation of immune responses and has been implicated in the development of autoimmune disorders. For example, studies have shown that CTTN is involved in the regulation of T cell function and that its expression is associated with the development of multiple sclerosis.

The potential drug targets for CTTN are vast and varied. Some studies have suggested that CTTN may be a potential target for cancer, neurodegenerative diseases, and autoimmune disorders. Others have suggested that it may be a potential drug target for diseases that involve the regulation of cell signaling, including neurotransmitter signaling, ion channels, and protein-protein interactions.

In addition to its potential drug targets, CTTN is also a potential biomarker for a wide range of diseases. Its expression has been shown to be involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive target for the development of diagnostic tests and therapies that can be used to treat these diseases.

The identification and characterization of CTTN as a potential drug target and biomarker has the potential to revolutionize our understanding of these diseases and lead to new treatments and therapies. Further research is needed to fully understand the role of CTTN in disease and to develop effective treatments.

Protein Name: Cortactin

Functions: Contributes to the organization of the actin cytoskeleton and cell shape (PubMed:21296879). Plays a role in the formation of lamellipodia and in cell migration. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Through its interaction with CTTNBP2, involved in the regulation of neuronal spine density (By similarity). Plays a role in focal adhesion assembly and turnover (By similarity). In complex with ABL1 and MYLK regulates cortical actin-based cytoskeletal rearrangement critical to sphingosine 1-phosphate (S1P)-mediated endothelial cell (EC) barrier enhancement (PubMed:20861316). Plays a role in intracellular protein transport and endocytosis, and in modulating the levels of potassium channels present at the cell membrane (PubMed:17959782). Plays a role in receptor-mediated endocytosis via clathrin-coated pits (By similarity). Required for stabilization of KCNH1 channels at the cell membrane (PubMed:23144454). Plays a role in the invasiveness of cancer cells, and the formation of metastases (PubMed:16636290)

The "CTTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets